Merck snares $269M in U.S. funding to prep manufacturing for Johnson & Johnson's COVID-19 vaccine
Merck's "wartime" coronavirus tie-up with Johnson & Johnson puts the vaccine giant on deck to support drug substance, formulation and vial-filling work in the U.S. And the government is chipping in with $269 million to equip two Merck manufacturing plants for the work.